Business Context and Reporting Period
This Form 8-K Current Report was filed by Aquestive Therapeutics, Inc. on March 20, 2026, covering events occurring on March 16, 2026. The filing primarily addresses executive leadership changes within the legal and compliance functions of the company.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel transitions and associated compensation arrangements.
Material Changes
- Executive Departure: Lori J. Braender will step down as Chief Legal Officer and Chief Compliance Officer effective April 2, 2026.
- Executive Appointment: Thomas A. Zalewski has been appointed as the new Chief Legal Officer and Chief Compliance Officer, effective April 2, 2026.
- Role Transition: Ms. Braender will remain employed to perform transition services and continue serving as Corporate Secretary through at least the end of the year.
Compensation, Outlook, and Risks
Separation Agreement Terms for Lori J. Braender:
- Salary: Current base salary continues through May 7, 2026. As Corporate Secretary, she will receive a base salary of $15,000 per month.
- Bonus: Entitled to a pro rata target annual bonus for 2026.
- Severance: Monthly payments for 12 months following May 7, 2026, equal to 1/12 of the sum of her base salary and target annual bonus.
- Benefits: Continuing coverage under group health and life insurance plans for 12 months.
- Equity: Full and immediate vesting on May 7, 2026, of all unvested stock options, RSUs, SARs, and Restricted Stock. Performance-based awards ending after this date will be assumed achieved at target.
- Change in Control: Severance protection applies if terminated without cause or for good reason in connection with a change in control.
Outlook and Risks: The filing does not provide updated financial guidance or discuss new material risks beyond the standard transition of executive duties. The appointment of Mr. Zalewski, a former Partner at Day Pitney LLP, suggests a focus on leveraging extensive experience in life sciences and healthcare regulatory matters.
Investor Verification Checklist
- Verify the effective date of Thomas A. Zalewski's appointment (April 2, 2026) and his prior experience at Day Pitney LLP.
- Confirm the specific terms of the Separation Agreement regarding the 12-month severance payments and immediate equity vesting for Ms. Braender.
- Review the attached Press Release (Exhibit 99.1) for any additional strategic context regarding the leadership change.
- Monitor future filings for the formal appointment of a new Chief Legal Officer if Mr. Zalewski's role changes or if further restructuring occurs.